ETFs Alaunos Therapeutics, Inc.

TCRT

US98973P3091

Biotechnology & Medical Research

Market Closed - Nasdaq 16:30:00 2026-09-04 EDT			5-day change	1st Jan Change
1.630 ^USD	-1.21%		+1.56%	-49.54%

08-14	Alaunos Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06-29	Alaunos Therapeutics Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment For Body Fat Percentage In 48-Day DIO Mouse Study	CI

ETFs positioned on Alaunos Therapeutics, Inc.

Name	YTD change	Weight	AuM
VANGUARD ALL-EQUITY ETF PORTFOLIO - CAD	+16.18%	0%	12,086 M€
UPAR ULTRA RISK PARITY ETF - USD	+5.88%	0%	59 M€
ALPHA ARCHITECT US EQUITY 2 ETF - USD	+11.48%	-.--%	513 M€

Alaunos Therapeutics, Inc. is a pre-clinical obesity and metabolic disorder and clinical-stage oncology-focused cell therapy company. The Company focuses on developing small molecules that are expected to be efficacious against obesity and other metabolic disorders. The Company is engaged in developing novel small molecule-based obesity therapeutics. The Companyâ€™s operations consist primarily of conducting research and development and raising capital to fund those efforts. The Company has not generated any revenues.

Employees

Sector

Biotechnology & Medical Research

More about the company